Relationship of serum beta-synuclein with blood biomarkers and brain atrophy.

Oeckl, Patrick; Anderl-Straub, Sarah; Danek, Adrian; Diehl-Schmid, Janine; Fassbender, Klaus; Fliessbach, Klaus; Halbgebauer, Steffen; Huppertz, Hans-Jürgen; Jahn, Holger; Kassubek, Jan; Kornhuber, Johannes; Landwehrmeyer, Bernhard; Lauer, Martin; Prudlo, Johannes; Schneider, Anja; Schroeter, Matthias L; Steinacker, Petra; Volk, Alexander E; Wagner, Matias; Winkelmann, Juliane; Wiltfang, Jens; Ludolph, Albert C; Otto, Markus

doi:10.1002/alz.12790

User: Guest

2023

Back
Back to start of result list
Permanent link for displayed object

Title:: Relationship of serum beta-synuclein with blood biomarkers and brain atrophy.
Document type:: Journal Article
Author(s):: Oeckl, Patrick; Anderl-Straub, Sarah; Danek, Adrian; Diehl-Schmid, Janine; Fassbender, Klaus; Fliessbach, Klaus; Halbgebauer, Steffen; Huppertz, Hans-Jürgen; Jahn, Holger; Kassubek, Jan; Kornhuber, Johannes; Landwehrmeyer, Bernhard; Lauer, Martin; Prudlo, Johannes; Schneider, Anja; Schroeter, Matthias L; Steinacker, Petra; Volk, Alexander E; Wagner, Matias; Winkelmann, Juliane; Wiltfang, Jens; Ludolph, Albert C; Otto, Markus
Abstract:: BACKGROUND: Recent data support beta-synuclein as a blood biomarker to study synaptic degeneration in Alzheimer's disease (AD). METHODS: We provide a detailed comparison of serum beta-synuclein immunoprecipitation - mass spectrometry (IP-MS) with the established blood markers phosphorylated tau 181 (p-tau181) (Simoa) and neurofilament light (NfL) (Ella) in the German FTLD consortium cohort (n = 374) and its relation to brain atrophy (magnetic resonance imaging) and cognitive scores. RESULTS: Serum beta-synuclein was increased in AD but not in frontotemporal lobar degeneration (FTLD) syndromes. Beta-synuclein correlated with atrophy in temporal brain structures and was associated with cognitive impairment. Serum p-tau181 showed the most specific changes in AD but the lowest correlation with structural alterations. NfL was elevated in all diseases and correlated with frontal and temporal brain atrophy. DISCUSSION: Serum beta-synuclein changes differ from those of NfL and p-tau181 and are strongly related to AD, most likely reflecting temporal synaptic degeneration. Beta-synuclein can complement the existing panel of blood markers, thereby providing information on synaptic alterations. HIGHLIGHTS: Blood beta-synuclein is increased in Alzheimer's disease (AD) but not in frontotemporal lobar degeneration (FTLD) syndromes. Blood beta-synuclein correlates with temporal brain atrophy in AD. Blood beta-synuclein correlates with cognitive impairment in AD. The pattern of blood beta-synuclein changes in the investigated diseases is different to phosphorylated tau 181 (p-tau181) and neurofilament light (NfL). «
BACKGROUND: Recent data support beta-synuclein as a blood biomarker to study synaptic degeneration in Alzheimer's disease (AD). METHODS: We provide a detailed comparison of serum beta-synuclein immunoprecipitation - mass spectrometry (IP-MS) with the established blood markers phosphorylated tau 181 (p-tau181) (Simoa) and neurofilament light (NfL) (Ella) in the German FTLD consortium cohort (n = 374) and its relation to brain atrophy (magnetic resonance imaging) and cognitive scores. RESULTS: Ser... »
Journal title abbreviation:: Alzheimers Dement
Year:: 2023
Journal volume:: 19
Journal issue:: 4
Pages contribution:: 1358-1371
Fulltext / DOI:: doi:10.1002/alz.12790
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/36129098
Print-ISSN:: 1552-5260
TUM Institution:: 303; 55; Institut für Humangenetik; Klinik und Poliklinik für Psychiatrie und Psychotherapie; Lehrstuhl für Neurogenetik (N.N.)
BibTeX